Local Anaesthetic Systemic Toxicity (LAST): The Lipid Rescue
Most poisonings arrive from the outside — a swallowed overdose, a bite, a bad batch. This one is different. Local anaesthetic systemic toxicity is a poisoning the clinician injects, in the operating theatre or the emergency department, in a fully awake patient, seconds before it happens. A nerve block that was meant to spare pain instead floods the bloodstream with a sodium-channel blocker, and the two most electrically excitable organs in the body — the brain and the heart — begin to fail in sequence. The reason every prescriber who wields a syringe of lidocaine must know it: the antidote is not a drug you reach for in cardiology. It is a bag of fat.
A healthy 30-year-old is having a shoulder repaired under an axillary nerve block. The anaesthetist injects a bolus of bupivacaine around the brachial plexus. A minute later the patient says her lips feel numb and there is a strange metallic taste in her mouth; her ears are ringing. Before anyone can respond she becomes agitated, then her whole body stiffens into a generalized seizure. The monitor alarms: the QRS complexes on the ECG are widening, the heart rate is falling, the blood pressure crashing. This is not an allergy and not a faint. A syringe of local anaesthetic has found its way into a vein, plasma levels have spiked, and the drug is now shutting down the sodium channels of her brain and heart at the same time. The team stops injecting, secures the airway — and calls for the bag of lipid.
The drug that was supposed to stay put
A local anaesthetic is a sodium-channel blocker with a very short address. Local anaesthetics — lidocaine, bupivacaine, ropivacaine, prilocaine — work by blocking voltage-gated sodium channels on nerve membranes. No sodium influx means no action potential, and no action potential means the nerve cannot signal pain. Injected next to a nerve, the drug is meant to act locally and stay locally, wearing off as it slowly diffuses away and is absorbed. The whole design assumes the drug reaches only the tissue in front of the needle. Toxicity is what happens when that assumption breaks and a high concentration reaches the systemic circulation — because the very same sodium channels that silence a nerve also run the electrical life of the brain and the heart. The mechanism this chapter builds on is taught in full under Central Nervous System / Analgesia & Anaesthesia, where local anaesthetic pharmacology and the sodium channel are the starting point.
How the plasma level climbs too high
There are two routes to a toxic plasma level, and they matter because they demand different discipline. The first is inadvertent intravascular injection: the needle tip sits in a vein or artery, and a dose meant to soak slowly into tissue is instead delivered straight into the blood as a bolus. This is the fast, dramatic form — symptoms within seconds to a minute, often mid-injection. The second is systemic absorption of an excessive dose: even perfectly placed, a local anaesthetic is absorbed from the tissues over time, and if the total dose exceeds what the body can handle, levels creep up over many minutes. This is why local anaesthetics carry a weight-based maximum safe dose. Highly vascular injection sites (intercostal, then caudal/epidural) absorb fastest and reach the highest levels for a given dose; the very young, the elderly, and patients with cardiac, hepatic or renal impairment tolerate less.
Think of a nerve block like watering a single potted plant. Done properly, the water pools in that one pot and slowly soaks in — exactly where you want it, harmless to the rest of the room. Inadvertent intravascular injection is like accidentally aiming the hose into a floor drain that runs straight to the house's main pipe: the same amount of water, but now it's coursing through the whole building's plumbing in seconds. Exceeding the maximum dose is the slower version — pouring so much into the pot that it overflows and seeps across the floor. Either way, water that was meant for one small pot ends up somewhere it can do damage. The drug did nothing unusual; it simply arrived where it was never supposed to be, in a concentration nerves elsewhere could not survive.
The toxidrome: CNS first, then the heart
LAST is a dose-dependent march, and the brain is the more sensitive organ — it complains first. As the plasma level rises, the central nervous system speaks before the heart does. The earliest signs are the classic warnings a conscious patient reports: numbness or tingling around the mouth and tongue, a metallic taste, ringing in the ears (tinnitus), blurred vision, light-headedness. As the level climbs, agitation and confusion appear, then frank generalized seizures — the paradoxical excitation phase, where the drug first knocks out inhibitory neurons and leaves excitatory ones unopposed. Push the level higher still and the excitation gives way to global CNS depression: drowsiness, coma, respiratory arrest. Only then, at the highest levels, does the cardiovascular system fail — and it fails hard. This ordered progression is the single most useful thing to memorize, because those early perioral tingles and that metallic taste are a free warning, seconds of grace to stop injecting before the seizure and the arrest.
The cardiac phase is where LAST kills. Blocking the fast sodium channels of cardiac muscle slows conduction: the PR interval and then the QRS widen, bradycardia sets in, contractility falls, and the blood pressure drops profoundly. At the extreme the rhythm degenerates into refractory ventricular tachycardia, ventricular fibrillation, or asystole. This is membrane-stabilising cardiotoxicity, and it is exactly the same physiological insult produced by a tricyclic antidepressant overdose — which is why LAST rhymes so closely with the Cardiovascular / Arrhythmias chapter on sodium-channel blockade and with the TCA-toxicity story: wide QRS, hypotension, and malignant arrhythmias from a drug that has jammed the heart's sodium channels shut.
Not all local anaesthetics are equally dangerous — bupivacaine is the villain. Lidocaine binds the sodium channel loosely and lets go quickly ("fast-in, fast-out"), so between beats the channel largely recovers. Bupivacaine binds tightly and dissociates slowly ("fast-in, slow-out"): at heart rates, the channel never fully recovers between beats, so blockade accumulates and the heart is far more likely to arrest — and far harder to resuscitate. That single kinetic fact is why bupivacaine cardiotoxicity is the classic exam answer for "most cardiotoxic local anaesthetic," why plain bupivacaine is never used for intravenous regional anaesthesia (Bier block), and why ropivacaine and levobupivacaine were developed as less cardiotoxic cousins.
- LAST is an iatrogenic emergency: too high a plasma level of a local anaesthetic poisons the excitable tissue of the CNS and heart.
- Two routes: inadvertent intravascular injection (fast, seconds) or exceeding the weight-based maximum dose (slower, minutes).
- Mechanism: blockade of voltage-gated sodium channels — the same channels that run nerve, brain and cardiac electrical activity.
- CNS first (perioral numbness, metallic taste, tinnitus, agitation → seizures → coma), then cardiovascular collapse.
- Cardiac toxicity: widening QRS, bradycardia, profound hypotension, refractory ventricular arrhythmias, arrest.
- Bupivacaine is the most cardiotoxic — tight, slow-dissociating sodium-channel binding that accumulates at heart rates.
Prevention: the toxicity you never have to treat
Because LAST is injected, it is one of the few poisonings you can genuinely prevent at the moment of dosing. Calculate and respect the weight-based maximum dose before drawing up — and remember it is milligrams per kilogram of lean body weight, not a fixed volume. Aspirate before injecting to check the needle is not in a vessel (a negative aspiration is reassuring but not perfect). Give the dose in fractionated increments with pauses, rather than one large bolus, so that an intravascular tip declares itself with early symptoms before the whole dose is in. Talk to the awake patient throughout and ask about tingling lips, taste or tinnitus — the early CNS warnings are a monitor no machine replaces. And use a small dose of adrenaline in the local anaesthetic mixture as an intravascular marker: an unexpected tachycardia after injection suggests the drug has reached the circulation. Ultrasound guidance, by letting you watch the needle tip and the spread of injectate, lowers the risk further.
Management: modified ACLS and the lipid antidote
The moment LAST is suspected, the injection stops and the clock starts. First, stop injecting and call for help. Secure the airway and give 100% oxygen — hypoxia and acidosis dramatically worsen sodium-channel toxicity, so airway and ventilation come before anything clever. Treat seizures with a benzodiazepine (they raise the seizure threshold without adding cardiac depression); avoid large doses of propofol in a haemodynamically unstable patient, since it is itself a cardiac depressant. If cardiac arrest occurs, run ACLS — but with LAST-specific modifications. Use small, incremental doses of adrenaline rather than the standard large boluses, because big adrenaline surges can worsen arrhythmias in the sodium-blocked heart. Avoid vasopressin, avoid calcium-channel blockers and beta-blockers, and reduce or avoid lidocaine as an antiarrhythmic — you would be adding another sodium-channel blocker to a heart already poisoned by one. Amiodarone is the preferred antiarrhythmic if one is needed. And above all, start the antidote early rather than late.
The antidote is intravenous lipid emulsion — the treatment known as "lipid rescue." The specific antidote for LAST is a 20% intravenous lipid emulsion (the same kind of soybean-oil emulsion used in parenteral nutrition, e.g. Intralipid). The dominant mechanism is elegantly simple: local anaesthetics are highly lipophilic, so a sudden bolus of fat in the bloodstream creates an expanded lipid compartment — a "lipid sink" — into which the drug partitions, pulling it off the sodium channels of cardiac tissue and lowering the free, active drug concentration at the heart. There are probably secondary benefits too: the fatty-acid load gives the poisoned myocardium an energy substrate and may have a direct cardiotonic effect. It is given as an initial bolus followed by a continuous infusion, with the bolus repeated for persistent instability and the infusion rate increased if the blood pressure stays low. You do not wait for full arrest — lipid emulsion is started for serious, evolving toxicity (seizures with cardiovascular signs, arrhythmia, hypotension), not only for a flatline.
Persist. LAST is one of the few cardiac arrests where prolonged resuscitation is genuinely worthwhile and full neurological recovery has followed an hour or more of CPR. The reason is mechanistic: the heart is not infarcted or structurally damaged, it is chemically blocked — and as lipid emulsion, metabolism and redistribution steadily pull the drug away from the sodium channels, a heart that looked unsalvageable can suddenly recover. So do not call it early. Keep going, keep the lipid running, and remember that cardiopulmonary bypass or ECMO is the ultimate bridge, buying time for the poison to clear when everything else is failing.
Agent: 20% intravenous lipid emulsion (Intralipid and equivalents). Indication: serious LAST — seizures with cardiovascular compromise, arrhythmia, hypotension, or arrest — given alongside airway support and modified ACLS. Mechanism: a "lipid sink" that partitions lipophilic local anaesthetic out of cardiac tissue, plus a likely cardiac energy/metabolic effect. Principle of dosing: an initial weight-based bolus, then a continuous infusion; repeat the bolus for persistent instability and up-titrate the infusion for ongoing hypotension, up to a recommended maximum total dose. Monitor: haemodynamics and rhythm; watch for very high lipid loads causing hypertriglyceridaemia or, rarely, pancreatitis. The lipid-sink idea is not unique to local anaesthetics — the same emulsion is a rescue option in overdose of other highly lipophilic cardiotoxic drugs, and it is discussed alongside the Enhanced-elimination & Antidotes chapter, where it sits next to lipid rescue for tricyclic antidepressant, calcium-channel-blocker and beta-blocker poisoning.
- Prevention: weight-based max dose, aspirate, fractionated incremental injection, talk to the awake patient, adrenaline as an intravascular marker, ultrasound guidance.
- First steps: stop injecting, call for help, airway and 100% oxygen — hypoxia and acidosis worsen the toxicity.
- Seizures: benzodiazepine; avoid large-dose propofol in an unstable patient.
- Modified ACLS: small incremental adrenaline, prefer amiodarone, avoid/reduce lidocaine, avoid vasopressin, CCBs and beta-blockers.
- Antidote: 20% IV lipid emulsion started early — a bolus then infusion — for serious evolving toxicity, not only for arrest.
- Resuscitate long: the heart is chemically blocked, not damaged, and can recover after prolonged CPR (± ECMO).
- Treating the QRS-widening cardiotoxicity of LAST by giving intravenous lidocaine as an antiarrhythmic — adding a second sodium-channel blocker to a heart already poisoned by one.
- Waiting for full cardiac arrest before giving lipid emulsion. It is started for serious, evolving toxicity — early lipid may prevent the arrest entirely.
- Stopping resuscitation too early. In LAST the myocardium is chemically blocked, not infarcted; prolonged CPR with lipid running has produced full recovery.
During an axillary block with bupivacaine, a patient reports perioral numbness and tinnitus, then has a generalized seizure; the ECG shows a widening QRS and the blood pressure falls. After stopping the injection, securing the airway with 100% oxygen and treating the seizure with a benzodiazepine, what is the specific antidote?
- LAST is an iatrogenic emergency: local anaesthetics block voltage-gated sodium channels, and too high a plasma level (intravascular injection or exceeding the weight-based max dose) poisons the CNS and heart.
- The toxidrome marches in order: CNS excitation (perioral numbness, metallic taste, tinnitus, agitation) → seizures → CNS depression, then cardiovascular collapse (wide QRS, bradycardia, hypotension, refractory arrhythmias). Bupivacaine is the most cardiotoxic.
- Prevent it at the needle: max-dose calculation, aspiration, fractionated incremental dosing, an awake talking patient, and adrenaline as an intravascular marker.
- Manage with airway/oxygen, benzodiazepines for seizures, modified ACLS (small adrenaline, prefer amiodarone, avoid lidocaine/vasopressin/CCBs), and the antidote — early 20% IV lipid emulsion (a "lipid sink") with prolonged resuscitation. The lipid-sink idea generalises to other lipophilic-drug overdoses.
- Goldfrank's Toxicologic Emergencies — Local Anesthetics; Lipid Emulsion antidote.
- Rang & Dale's Pharmacology — Local anaesthetics: mechanism, systemic toxicity and structure–activity.
- Katzung Basic & Clinical Pharmacology — Local Anesthetics.
- Neal JM, et al. American Society of Regional Anesthesia and Pain Medicine (ASRA) Checklist and Practice Advisory on Local Anesthetic Systemic Toxicity.
- Association of Anaesthetists (AAGBI) — Management of Severe Local Anaesthetic Toxicity guideline (QRH).
- Weinberg GL. Lipid emulsion infusion: resuscitation for local anesthetic and other drug overdose. Anesthesiology.
